PhoreMost
PhoreMost is a next-generation targeted protein degradation (TPD) company developing a pipeline of first-in-class and best-in-class degrader therapeutics within oncology and inflammation. TPD is a promising new way to eliminate toxic or disease-associated targets from cells, with degradation-based therapies now becoming an integral approach to tackling undruggable targets. However, despite there being over 600 known E3 ligases, the pharma industry is currently reliant upon a very small number, such as Cereblon, for degrader-based drug development. PhoreMost is unlocking the full potential of TPD and has pioneered the use of mini-protein based engineering via its proprietary platforms, SITESEEKER and GlueSEEKER™, towards developing novel therapeutic approaches to TPD.The Company has progressed multiple next-generation ligase programmes through proof-of-concept and is advancing multiple degrader assets towards preclinical studies. PhoreMost also has a number of disclosed alliances with partners, including Roche, Boehringer Ingelheim and Sentinel Oncology.Content by PhoreMost
| 4 min read
A new platform may finally unlock the rules behind molecular glue degraders, turning chance discoveries into programmable therapeutics.
| 2 min read
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
Page 1 of 1 - 2 Total Items
